Journal
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
Volume 15, Issue 2, Pages 157-167Publisher
SPRINGER
DOI: 10.1007/s11154-013-9265-5
Keywords
Adiponectin; Signaling; Metabolism; Diabetes; Cardiovascular disease; Cancer
Categories
Funding
- Canadian Institutes of Health Research
- Canadian Diabetes Association
- Heart & Stroke Foundation of Canada
- Heart & Stroke Foundation of Ontario
Ask authors/readers for more resources
The increased prevalence of obesity has mandated extensive research focused on mechanisms responsible for associated clinical complications. Emerging from the focus on adipose tissue biology as a vitally important adipokine is adiponectin which is now believed to mediate anti-diabetic, anti-atherosclerotic, anti-inflammatory, cardioprotective and cancer modifying actions. Adiponectin mediates these primarily beneficial effects via direct signaling effects and via enhancing insulin sensitivity via crosstalk with insulin signaling pathways. Reduced adiponectin action is detrimental and occurs in obesity via decreased circulating levels of adiponectin action or development of adiponectin resistance. This review will focus on cellular mechanisms of adiponectin action, their crosstalk with insulin signaling and the resultant role of adiponectin in cardiovascular disease, diabetes and cancer and reviews data from in vitro cell based studies through animal models to clinical observations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available